Compare SCL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | GLUE |
|---|---|---|
| Founded | 1932 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | SCL | GLUE |
|---|---|---|
| Price | $50.63 | $25.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 154.8K | ★ 2.3M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.98 | 0.25 |
| Revenue | ★ $2,303,837,000.00 | $181,538,000.00 |
| Revenue This Year | $8.79 | $84.02 |
| Revenue Next Year | $8.14 | N/A |
| P/E Ratio | ★ $25.28 | $92.23 |
| Revenue Growth | 5.35 | ★ 1112.27 |
| 52 Week Low | $41.82 | $3.50 |
| 52 Week High | $65.89 | $25.15 |
| Indicator | SCL | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 73.52 | 75.70 |
| Support Level | $46.70 | $13.69 |
| Resistance Level | $47.77 | $17.81 |
| Average True Range (ATR) | 1.13 | 1.58 |
| MACD | 0.23 | 0.64 |
| Stochastic Oscillator | 86.87 | 95.28 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.